|
Products |
| Products |
|
Diseases |  |
News |  |
| «12345678910111213...39313932» |
- Puyouheng (pucotenlimab) / Taizhou Hanzhong Biopharma, Lepu Med, Inlyta (axitinib) / Pfizer
Axitinib in Combination With anti (1st Floor, 1D Meeting Room) - Oct 2, 2024 - Abstract #CSCO2024CSCO_594;
Study group: [CSCO Malignant Melanoma Expert Committee]
- Keytruda (pembrolizumab) / Merck (MSD)
A Phase II study of Pembrolizumab combination with Temozolomide as 1L treatment for Chinese metastatic acral melanoma patients (1st Floor, 1D Meeting Room) - Oct 2, 2024 - Abstract #CSCO2024CSCO_581;
Study group: [CSCO Malignant Melanoma Expert Committee] Study group: [CSCO Malignant Melanoma Expert Committee]
- AiRuiKa (camrelizumab) / HLB Bio Group, famitinib (SHR 1020) / Jiangsu Hengrui Pharma
Phase II clinical trial of camrelizumab combined with famitinib for immunotherapy-treated advanced acral and mucosal melanoma (1st Floor, 1D Meeting Room) - Oct 2, 2024 - Abstract #CSCO2024CSCO_580;
Study group: [CSCO Malignant Melanoma Expert Committee] Study group: [CSCO Malignant Melanoma Expert Committee]
- Lunsumio (mosunetuzumab-axgb) / Roche
Safety and Efficacy of Mosunetuzumab Monotherapy in Chinese Patients with Relapsed or Refractory Follicular Lymphoma (2nd Floor, Xiamen Hall 3) - Oct 2, 2024 - Abstract #CSCO2024CSCO_552;
Study group: [CSCO Malignant Melanoma Expert Committee] Study group: [CSCO Leukemia Expert Committee, CSCO Lymphoma Expert Committee]
- Opdivo (nivolumab) / BMS, Lenvima (lenvatinib) / Eisai, Merck (MSD), Yervoy (ipilimumab) / BMS
Effect of nivolumab (NIVO) plus ipilimumab (IPI) versus lenvatinib (LEN) or sorafenib (SOR) as first-line treatment for patients with unresectable/advanced hepatocellular carcinoma (HCC): a Chinese population analysis of the CheckMate 9DW study (2nd Floor, Xiamen Hall 2) - Oct 2, 2024 - Abstract #CSCO2024CSCO_543;
Study group: [CSCO Leukemia Expert Committee, CSCO Lymphoma Expert Committee] Study group: [CSCO Liver Cancer Expert Committee]
- Tevimbra (tislelizumab-jsgr) / BeiGene
Impact of First-Line Treatment with Tislelizumab on Health-Related Quality of Life in Chinese Patients with Unresectable Hepatocellular Carcinoma (2nd Floor, Xiamen Hall 2) - Oct 2, 2024 - Abstract #CSCO2024CSCO_542;
Study group: [CSCO Liver Cancer Expert Committee] Study group: [CSCO Liver Cancer Expert Committee]
- Keytruda (pembrolizumab) / Merck (MSD)
Phase 3 study of neoadjuvant pembrolizumab or placebo plus chemotherapy, followed by adjuvant pembrolizumab or placebo plus endocrine therapy for early-stage high-risk estrogen receptor-positive, HER2-negative breast cancer: KEYNOTE-756 (Level 1, Hall 1G) - Oct 2, 2024 - Abstract #CSCO2024CSCO_497;
Study group: [CSCO Liver Cancer Expert Committee] Study group: [CSCO Breast Cancer Expert Committee]
- Verzenio (abemaciclib) / Eli Lilly
The safety of Abemaciclib among advanced breast cancer patients in China: interim results from a prospective, multicenter, observational study (Level 1, Hall 1G) - Oct 2, 2024 - Abstract #CSCO2024CSCO_495;
Study group: [CSCO Breast Cancer Expert Committee] Study group: [CSCO Breast Cancer Expert Committee]
- sacituzumab tirumotecan (MK-2870) / Merck (MSD), Keytruda (pembrolizumab) / Merck (MSD)
TroFuse-019: A Phase 3 Study of Adjuvant Pembrolizumab With or Without Sacituzumab Tirumotecan (sac-TMT) for Resectable Stage II (1st Floor Concert Hall) - Oct 2, 2024 - Abstract #CSCO2024CSCO_459;
Study group: [CSCO Breast Cancer Expert Committee] Study group: [CSCO Non-Small Cell Lung Cancer Expert Committee]
- culmerciclib (TQB3616) / Sino Biopharm
TQB3616 combined with fulvestrant in the treatment of hormone receptor-positive, HER2-negative advanced breast cancer: a randomized, double-blind, parallel-controlled phase 3 clinical trial (2nd Floor Straits Room) - Oct 2, 2024 - Abstract #CSCO2024CSCO_419;
Study group: [CSCO Non-Small Cell Lung Cancer Expert Committee] Study group: [Organizing Committee]
- Ibrance (palbociclib) / Pfizer, inavolisib (GDC-0077) / Roche
Inavolisib or placebo in combination with palbociclib and fulvestrant in patients with PIK3CA-mutated, hormone receptor-positive, HER2-negative locally advanced or metastatic breast cancer: Phase III INAVO120 randomized trial primary and additional analys (2nd Floor Straits Room) - Oct 2, 2024 - Abstract #CSCO2024CSCO_417;
Study group: [Organizing Committee] Study group: [Organizing Committee]
- LBL-024 / Leads Biolabs
Phase I/II clinical study of LBL-024, a bispecific antibody targeting PD-L1 and 4-1BB, in patients with advanced malignancies and neuroendocrine cancer (2nd Floor Straits Room) - Oct 2, 2024 - Abstract #CSCO2024CSCO_410;
Study group: [Organizing Committee] Study group: [Organizing Committee]
- Tevimbra (tislelizumab-jsgr) / BeiGene, LBL-007 / BeiGene
Phase Ib/II study of the anti-LAG-3 antibody LBL-007 combined with the anti-PD-1 antibody tislelizumab (2nd Floor Straits Room) - Oct 2, 2024 - Abstract #CSCO2024CSCO_406;
Study group: [Organizing Committee] Study group: [Organizing Committee]
- Avastin (bevacizumab) / Roche, iparomlimab/tuvonralimab (PSB205) / Sound Biologics, Qilu Pharma
Interim report of a randomized, controlled, open-label, multicenter, adaptively designed phase 2/3 clinical study (DUBHE-H-308 trial) of ipallitovirizumab (QL1706) combined with bevacizumab and/or chemotherapy as first-line treatment for advanced hepatocellular carcinoma (2nd Floor Straits Room) - Oct 2, 2024 - Abstract #CSCO2024CSCO_404;
Study group: [Organizing Committee] Study group: [Organizing Committee]
- Loqtorzi (toripalimab-tpzi) / Shanghai Junshi Biosci, Coherus Biosci, Avastin (bevacizumab) / Roche
Toripalimab combined with bevacizumab versus sorafenib as first-line treatment for advanced hepatocellular carcinoma: a randomized, controlled, open-label, international multicenter registration phase III study in the Asia-Pacific region (2nd Floor Straits Room) - Oct 2, 2024 - Abstract #CSCO2024CSCO_400;
Study group: [Organizing Committee] Study group: [Organizing Committee]
- Inlyta (axitinib) / Pfizer, Loqtorzi (toripalimab-tpzi) / Shanghai Junshi Biosci, Coherus Biosci
A single-arm phase II trial: neoadjuvant treatment of locally advanced clear cell renal carcinoma with toripalimab combined with axitinib (Meeting Room 1B, Level 1) - Oct 2, 2024 - Abstract #CSCO2024CSCO_298;
Study group: [Organizing Committee] Study group: [CSCO Renal Cancer Expert Committee]
- Brukinsa (zanubrutinib) / BeiGene, Rituxan (rituximab) / Roche
Zanubrutinib combined with R-CHOP in the treatment of newly diagnosed double-expressing lymphoma: a multicenter, prospective, single-arm phase II clinical study (B8 3rd Floor Sea View Room 3) - Oct 2, 2024 - Abstract #CSCO2024CSCO_276;
Study group: [CSCO Renal Cancer Expert Committee] Study group: [Organizing Committee]
- Yinuokai (orelabrutinib) / InnoCare, Biogen, Rituxan (rituximab) / Roche
Preliminary results of R-MTO (rituximab, methotrexate, thiotepa, orelabrutinib) induction regimen followed by autologous stem cell transplantation as first-line treatment for newly diagnosed primary central nervous system lymphoma. (B8 3rd Floor Sea View Room 3) - Oct 2, 2024 - Abstract #CSCO2024CSCO_274;
Study group: [Organizing Committee] Study group: [Organizing Committee]
- Xpovio (selinexor) / Karyopharm, Rituxan (rituximab) / Roche
Xpo-1 Inhibitor Selinexor In Combination With Rchop Is Aneffective Chemotherapy Regimen For Patients With Double/Triple-Hit Large B-Cell Lymphoma (B8 3rd Floor Sea View Room 3) - Oct 2, 2024 - Abstract #CSCO2024CSCO_272;
Study group: [Organizing Committee] Study group: [Organizing Committee]
- AiRuiKa (camrelizumab) / HLB Bio Group, Aidixi (disitamab vedotin) / Pfizer
Efficacy and safety of Disitamab vedotin (RC48) combined with camrelizumab and S-1 for neoadjuvant therapy of locally advanced gastric cancer with HER2 overexpression: Preliminary results of a prospective, single-arm, phase II study (B8 3rd Floor Sea View Room 3) - Oct 2, 2024 - Abstract #CSCO2024CSCO_263;
Study group: [Organizing Committee] Study group: [Organizing Committee]
- Loqtorzi (toripalimab-tpzi) / Shanghai Junshi Biosci, Coherus Biosci, KD6001 / Shanghai Kanda Biotech
Phase Ib/II clinical study on the safety and efficacy of KD6001 combined with toripalimab in the treatment of advanced melanoma (B8 3rd Floor Sea View Room 3) - Oct 2, 2024 - Abstract #CSCO2024CSCO_257;
Study group: [Organizing Committee] Study group: [Organizing Committee]
- IBI-363 / Innovent Biologics
Efficacy and Safety of PD-1/IL-2?-bias bispecific antibody fusion protein IBI363 in patients with advanced melanoma: results from a phase 2 study (B8 3rd Floor Sea View Room 3) - Oct 2, 2024 - Abstract #CSCO2024CSCO_255;
Study group: [Organizing Committee] Study group: [Organizing Committee]
- Loqtorzi (toripalimab-tpzi) / Shanghai Junshi Biosci, Coherus Biosci
Toripalimab versus dacarbazine as first-line treatment for advanced melanoma: a multicenter, randomized, controlled, open-label phase III clinical study (B8 3rd Floor Sea View Room 3) - Oct 2, 2024 - Abstract #CSCO2024CSCO_253;
Study group: [Organizing Committee] Study group: [Organizing Committee]
- Yidafan (ivonescimab) / Akesobio, Summit Therapeutics
Interpretation of a phase II study (AK112-205) of perioperative ivocizumab alone or in combination with chemotherapy for the treatment of resectable non-small cell lung cancer (B8 3rd Floor Sea View Room 3) - Oct 2, 2024 - Abstract #CSCO2024CSCO_250;
Study group: [Organizing Committee] Study group: [Akeso Pharmaceuticals Co., Ltd.]
- Keytruda (pembrolizumab) / Merck (MSD), Yidafan (ivonescimab) / Akesobio, Summit Therapeutics
Interpretation of the Phase III study (HARMONi-2/AK112-303) of ivocizumab monotherapy versus pembrolizumab monotherapy as first-line treatment for PD-L1-positive non-small cell lung cancer (B8 3rd Floor Sea View Room 3) - Oct 2, 2024 - Abstract #CSCO2024CSCO_249;
Study group: [Akeso Pharmaceuticals Co., Ltd.] Study group: [Akeso Pharmaceuticals Co., Ltd.]
- Kanglaite Injection (KLTi) / Zhejiang Kanglaite Pharma
A study on the survival benefit and real-world safety of Kanglaite injection in the treatment of advanced non-small cell lung cancer (B8 Level 3 Sea View Room 2) - Oct 2, 2024 - Abstract #CSCO2024CSCO_233;
Study group: [Akeso Pharmaceuticals Co., Ltd.] Study group: [Jiangxi Kanglaite Pharmaceutical Co., Ltd.]
- AiRuiKa (camrelizumab) / HLB Bio Group
A Randomised, Multicentre, Phase II Trial of Camrelizumab with or without Metastasis-directed Stereotactic Body Radiotherapy in Recurrent or Metastatic Nasopharyngeal Carcinoma (Meeting Room 1E, Level 1) - Oct 2, 2024 - Abstract #CSCO2024CSCO_207;
Study group: [Jiangxi Kanglaite Pharmaceutical Co., Ltd.] Study group: [CSCO Tumor Radiation Therapy Expert Committee]
- AiTan (rivoceranib) / HLB Bio Group, AiRuiKa (camrelizumab) / HLB Bio Group
Study on the efficacy and safety of carrelizumab and apatinib combined with neoadjuvant concurrent chemoradiotherapy in the treatment of MSS locally advanced rectal cancer. (Meeting Room 1E, Level 1) - Oct 2, 2024 - Abstract #CSCO2024CSCO_205;
Study group: [CSCO Tumor Radiation Therapy Expert Committee] Study group: [CSCO Tumor Radiation Therapy Expert Committee]
- Tecentriq (atezolizumab) / Roche
Efficacy of radiotherapy combined with atezolizumab or docetaxel in patients with previously treated advanced non-small cell lung cancer: a PSM-IPTW cohort study (Meeting Room 1E, Level 1) - Oct 2, 2024 - Abstract #CSCO2024CSCO_203;
Study group: [CSCO Tumor Radiation Therapy Expert Committee] Study group: [CSCO Tumor Radiation Therapy Expert Committee]
- Keytruda (pembrolizumab) / Merck (MSD)
Pembrolizumab Plus Gemcitabine and Cisplatin Versus Placebo Plus Gemcitabine and Cisplatin as First-Line Therapy for Advanced Biliary Tract Cancer: Results for the China Subpopulation From the Phase 3 KEYNOTE-966 Study (2nd Floor, Xiamen Hall 2) - Oct 2, 2024 - Abstract #CSCO2024CSCO_131;
Study group: [CSCO Tumor Radiation Therapy Expert Committee] Study group: [CSCO Biliary Tract Tumor Expert Committee]
- AiRuiKa (camrelizumab) / HLB Bio Group
Neoadjuvant Chemotherapy Combined with Camrelizumab for Resectable Locally Advanced Esophageal Squamous Cell Carcinoma: A Prospective Cohort Study (2nd Floor, Xiamen Hall 1) - Oct 2, 2024 - Abstract #CSCO2024CSCO_99;
Study group: [CSCO Biliary Tract Tumor Expert Committee] Study group: [CSCO Esophageal Cancer Expert Committee]
- Tevimbra (tislelizumab-jsgr) / BeiGene, sitravatinib (MGCD516) / BeiGene
A Phase 2 Study of Sitravatinib in Combination with Tislelizumab Versus Chemotherapy in Patients with Locally Advanced Unresectable or Metastatic Esophageal Squamous Cell Carcinoma that Progressed on or after Anti (2nd Floor, Xiamen Hall 1) - Oct 2, 2024 - Abstract #CSCO2024CSCO_96;
Study group: [CSCO Esophageal Cancer Expert Committee] Study group: [CSCO Esophageal Cancer Expert Committee]
- Tecentriq (atezolizumab) / Roche
IMpower010: Final DFS and second OS interim analysis result from Asian patients after ?5 years of follow-up of a Phase III study of adjuvant atezolizumab vs best supportive care in resected stage IB-IIIA (1st Floor Concert Hall) - Oct 2, 2024 - Abstract #CSCO2024CSCO_57;
Study group: [CSCO Esophageal Cancer Expert Committee] Study group: [CSCO Non-Small Cell Lung Cancer Expert Committee]
- Hetronifly (serplulimab) / Fosun Pharma
A phase 3 study of serplulimab plus chemotherapy as first-line treatment in advanced squamous non-small-cell lung cancer: ASTRUM-004 Chinese subgroup (1st Floor Concert Hall) - Oct 2, 2024 - Abstract #CSCO2024CSCO_55;
Study group: [CSCO Non-Small Cell Lung Cancer Expert Committee] Study group: [CSCO Non-Small Cell Lung Cancer Expert Committee]
- || AFM24 / Affimed
Trial completion date, Trial primary completion date, Combination therapy, Metastases: AFM24-102: Study to Assess AFM24 in Combination with Atezolizumab in Selected Advanced/Metastatic EGFR-expressing Cancers (clinicaltrials.gov) - Oct 1, 2024
P1/2, N=148, Recruiting, Sponsor: Affimed GmbH
Study group: [CSCO Non-Small Cell Lung Cancer Expert Committee] Trial completion date: Jun 2025 --> Nov 2025 | Trial primary completion date: Sep 2024 --> Feb 2025
- |||| Bavencio (avelumab) / EMD Serono
Trial completion date, Trial primary completion date, Real-world evidence, Real-world, Metastases: AVENANCE: A NON-INTERVENTIONAL STUDY ON AVELUMAB USE IN PATIENTS WITH ADVANCED OR METASTATIC UROTHELIAL CARCINOMA (clinicaltrials.gov) - Oct 1, 2024
P=N/A, N=599, Active, not recruiting, Sponsor: Pfizer
Trial completion date: Jun 2025 --> Nov 2025 | Trial primary completion date: Sep 2024 --> Feb 2025 Trial completion date: Jun 2024 --> Mar 2025 | Trial primary completion date: Jun 2024 --> Mar 2025
- ||| Trial completion date, Trial suspension, Trial primary completion date, Metastases: EBV Specific Cytokine Secreting TCR-T Cells in the Treatment of EBV-Positive Metastatic/Refractory Nasopharyngeal Carcinoma (clinicaltrials.gov) - Oct 1, 2024
P1/2, N=20, Suspended, Sponsor: Xinqiao Hospital of Chongqing
Trial completion date: Jun 2024 --> Mar 2025 | Trial primary completion date: Jun 2024 --> Mar 2025 Trial completion date: Aug 2023 --> Dec 2024 | Recruiting --> Suspended | Trial primary completion date: Aug 2023 --> Dec 2024
- || lerapolturev (PVS-RIPO) / Istari Oncology
Trial completion, Trial completion date, Trial primary completion date, Checkpoint inhibition, IO biomarker: LUMINOS-101: Lerapolturev (PVSRIPO) and Pembrolizumab in Patients with Recurrent Glioblastoma (clinicaltrials.gov) - Oct 1, 2024
P2, N=25, Completed, Sponsor: Istari Oncology, Inc.
Trial completion date: Aug 2023 --> Dec 2024 | Recruiting --> Suspended | Trial primary completion date: Aug 2023 --> Dec 2024 Active, not recruiting --> Completed | Trial completion date: Mar 2024 --> Jun 2024 | Trial primary completion date: Mar 2024 --> Jun 2024
- | Keytruda (pembrolizumab) / Merck (MSD)
Enrollment closed, Enrollment change, Trial completion date, Trial primary completion date, Combination therapy, Checkpoint inhibition, Metastases: Quad Shot Radiotherapy in Combination With Immune Checkpoint Inhibition (clinicaltrials.gov) - Oct 1, 2024
P2, N=21, Active, not recruiting, Sponsor: Wake Forest University Health Sciences
Active, not recruiting --> Completed | Trial completion date: Mar 2024 --> Jun 2024 | Trial primary completion date: Mar 2024 --> Jun 2024 Suspended --> Active, not recruiting | N=15 --> 21 | Trial completion date: Dec 2024 --> Dec 2025 | Trial primary completion date: Dec 2024 --> Oct 2023
- | Keytruda (pembrolizumab) / Merck (MSD)
Trial completion date, Trial primary completion date, Metastases: Docetaxel/Pembrolizumab in Head and Neck Squamous Cell Carcinoma (clinicaltrials.gov) - Oct 1, 2024
P2, N=27, Recruiting, Sponsor: Hokkaido University Hospital
Suspended --> Active, not recruiting | N=15 --> 21 | Trial completion date: Dec 2024 --> Dec 2025 | Trial primary completion date: Dec 2024 --> Oct 2023 Trial completion date: May 2024 --> Nov 2025 | Trial primary completion date: Jan 2024 --> Nov 2024
- ||| Arzerra (ofatumumab) / Novartis, Genmab, Copiktra (duvelisib) / Secura Bio, Yakult Honsha
P3 data, Journal: The phase III DUO trial of PI3K inhibitor duvelisib versus ofatumumab in relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma: final analysis including overall survival. (Pubmed Central) - Oct 1, 2024
Trial completion date: May 2024 --> Nov 2025 | Trial primary completion date: Jan 2024 --> Nov 2024 Not available.
- | Xalkori (crizotinib) / Pfizer
Biomarker, Journal: Safety, Efficacy and Biomarker Analysis of Crizotinib in MET Mutated Non-Small Cell Lung Cancer - Results from the Drug Rediscovery Protocol. (Pubmed Central) - Oct 1, 2024
Not available. Crizotinib is a valuable treatment option in METmut aNSCLC.
- | Ibrance (palbociclib) / Pfizer
Journal: A genome-wide CRISPR/Cas9 knockout screen identifies SEMA3F gene for resistance (Pubmed Central) - Oct 1, 2024
Our observation provided the first evidence of SEMA3F as a regulator of sensitivity to CDK4/6 inhibitors in breast cancer. The detailed mechanisms of resistance deserve further functional studies to develop the better strategy to overcome resistance in CDK4/6 inhibitors.
- | Kimmtrak (tebentafusp-tebn) / Immunocore, Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
Retrospective data, Journal, PD(L)-1 Biomarker, IO biomarker, Metastases: Immunotherapy response and resistance in patients with advanced uveal melanoma: a retrospective cohort study. (Pubmed Central) - Oct 1, 2024
ImPERCIST5 and RECIST v1.1 are valuable tools in the radiological response assessment, but both methods display limitations. Accurate biomarkers to stratify patients at risk for disease progression and future translational studies to investigate mechanisms of response and resistance are required.
- | Ibrance (palbociclib) / Pfizer, Mekinist (trametinib) / Novartis, BeiGene
Retrospective data, Journal, Combination therapy, Metastases: Trametinib in combination with hydroxychloroquine or palbociclib in advanced metastatic pancreatic cancer: data from a retrospective, multicentric cohort (AIO AIO-TF/PAK-0123). (Pubmed Central) - Oct 1, 2024
Accurate biomarkers to stratify patients at risk for disease progression and future translational studies to investigate mechanisms of response and resistance are required. THCQ and TP are not effective in patients with advanced PDAC harboring KRAS mutations or alterations in MAPK/CDKN2A/B.
- | Rituxan (rituximab) / Roche
Journal, Real-world evidence, Real-world: Outcome of patients with diffuse large B-cell lymphoma and testicular involvement - real world data. (Pubmed Central) - Oct 1, 2024
Majority (84.3%) received CNS prophylaxis with similar rates of prophylactic methotrexate (intravenous 19.1% vs. 16.6%, intrathecal 40.8% vs. 40.4%, or both 24.2% vs. 27.8%) between PTL and T-DLBCL (p?=?0.89)...Methotrexate prophylaxis did not alter CNS relapse risk. Prognosis of CNS relapse is particularly poor in T-DLBCL.
- | Keytruda (pembrolizumab) / Merck (MSD), Retevmo (selpercatinib) / Eli Lilly
Journal, HEOR, Cost-effectiveness, Cost effectiveness: Cost-effectiveness analysis of selpercatinib versus chemotherapy and pembrolizumab in the first-line treatment of rearranged during transfection fusion-positive non-small cell lung cancer in the United States. (Pubmed Central) - Oct 1, 2024
Prognosis of CNS relapse is particularly poor in T-DLBCL. From the perspective of the US payer, selpercatinib is not cost-effective compared to chemotherapy and pembrolizumab for first-line treatment in patients with RET fusion-positive NSCLC.
- | Leukeran (chlorambucil) / GSK, Rituxan (rituximab) / Roche
Journal, Real-world evidence, Real-world: Real-world data for marginal zone lymphoma patients in the French REALYSA cohort: The REALMA study. (Pubmed Central) - Oct 1, 2024
At end of first line, overall response rate was 93% among treated patients with 75% of complete response. This French nationwide study provided for the first time prospective RWD on clinical characteristics, initial management and treatment response of MZL patients.
- || JNJ-9530 / J&J
P1 data, Journal: C-CAR066, a novel fully human anti-CD20 CAR-T therapy for relapsed or refractory large B-cell lymphoma after failure of anti-CD19 CAR-T therapy: A phase I clinical study. (Pubmed Central) - Oct 1, 2024
P1
C-CAR066 demonstrated a manageable safety profile and promising efficacy in patients in whom prior anti-CD19 CAR-T therapies had failed, providing a promising treatment option for those patients. This trial was registered with ClinicalTrials.gov, NCT04316624 and NCT04036019.
- || Rituxan (rituximab) / Roche
Clinical, Retrospective data, Journal: A multicenter retrospective study on comparing the efficacy and safety of the therapy of intermittent cyclophosphamide and corticosteroids versus rituximab for primary membranous nephropathy. (Pubmed Central) - Oct 1, 2024
This trial was registered with ClinicalTrials.gov, NCT04316624 and NCT04036019. There was no difference in remission rates and safety between RTX versus intermittent intravenous CTX combined with oral corticosteroid treatment for patients with PMN within 2